Results 111 to 120 of about 282,663 (297)

Updates in the management of polycythemia vera and essential thrombocythemia

Therapeutic Advances in Hematology, 2019
Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar   +1 more source

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

Haematologica, 2009
To further characterize JAK2 exon 12 mutations, we performed molecular screening in 409 patients with polycythemia vera or unclear erythrocytosis with unmutated JAK2V617. The frequency of JAK2exon12 mutations was 10/63 (15.9%) in PV but only 5/346 (1.4%)
Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Thomas Geer, Peter Müller, Johann Mittermüller, Petro Petrides, Rudolf Schlag, Reiner Sandner, Johannes Selbach, Hans Rainer Slawik, Hans Werner Tessen, Jürgen Wehmeyer, Wolfgang Kern, Torsten Haferlach   +14 more
doaj   +1 more source

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study [PDF]

, 2013
Item does not contain fulltextReliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response.
A Pardanani, A Quintás-Cardama, A Tefferi, A Tefferi, AJ Bench, AJ Bench, AM Vannucchi, AM Vannucchi, C James, C Nielsen, D Grimwade, E Jabbour, E Lippert, E Lippert, EJ Baxter, F Dazzi, F Passamonti, FP Santos, G Barosi, H Alchalby, J Gabert, J Kittur, J Mason, JD Merker, JJ Kiladjian, JJ Kiladjian, JT Reilly, KL Spindler, MJ Pongers-Willemse, N Kröger, N Kröger, NK Steckel, O Benjamini, P Guglielmelli, R Flora, R Kralovics, RH Nussenzveig, RL Levine, RL Levine, S Schnittger, S Verstovsek, S Verstovsek, SH Swerdlow, T Ishii, T Lange, TS Larsen, TS Larsen, U Siebolts, V De Stefano, VH van der Velden, X Xu, YL Wang   +51 more
core   +2 more sources

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Blood Advances, 2016
Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; we describe the occurrence and prognostic relevance of DNA sequence variants ...
A. Tefferi, T. Lasho, P. Guglielmelli, C. Finke, G. Rotunno, Y. Elala, Annalisa Pacilli, C. Hanson, A. Pancrazzi, R. Ketterling, C. Mannarelli, D. Barraco, Tiziana Fanelli, A. Pardanani, N. Gangat, A. Vannucchi   +15 more
semanticscholar   +1 more source

Non‐Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1‐Negative Myeloproliferative Neoplasms

Liver International, Volume 45, Issue 6, June 2025.
ABSTRACT Background & Aims The course of BCR::ABL1‐negative myeloproliferative neoplasms (MPN) is frequently complicated by thromboembolic events in the splanchnic venous system, resulting in portal hypertension (PH). Therefore, the introduction of spleen stiffness measurement (SSM) might improve the diagnosis of PH.
Lorenz Balcar, Lina Degenfeld‐Schonburg, Can Hopp, Georg Kramer, Irene Graf, Lucie Simonis, Christian Sillaber, Stephanie Kalteis, Heinz Gisslinger, Tobias Meischl, Albert Friedrich Stättermayer, Mattias Mandorfer, Gerlinde Mitterbauer‐Hohendanner, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Maria‐Theresa Krauth, Georg Semmler   +17 more
wiley   +1 more source

Treatment of polycythemia vera [PDF]

Vnitřní lékařství, 2018
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation resulting in erythrocytosis, leukocytosis and thrombocytosis. Survival is reduced compared with general population.
openaire   +3 more sources

Superior Vena Cava Syndrome in a Patient with Polycytemia Vera: Diagnosis and Treatment

Cardiology Research and Practice, 2010
Polycythemia vera is a myeloproliferative disorder characterized by thrombotic complications both in the arterial and venous systems. We report the case of a 55-year-old patient affected by polycythemia vera, presenting with acute superior vena cava ...
Salvatore Lentini, Mario Barone, Filippo Benedetto, Francesco Spinelli   +3 more
doaj   +1 more source

Mechanisms of thrombogenesis in polycythemia vera

Blood Reviews, 2015
Thrombotic and cardiovascular events are among the leading causes of death for patients with polycythemia vera (PV), and thrombosis history is a key criterion for patient risk stratification and treatment strategy. Little is known, however, about mechanisms of thrombogenesis in patients with PV.
Srdan Verstovsek, Laura C. Michaelis, Michael H. Kroll   +2 more
openaire   +3 more sources

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Blood Cancer Journal, 2018
Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients ...
E. Verger, J. Soret-Dulphy, N. Maslah, L. Roy, J. Rey, Z. Ghrieb, R. Kralovics, H. Gisslinger, B. Grohmann-Izay, C. Klade, C. Chomienne, S. Giraudier, B. Cassinat, J. Kiladjian   +13 more
semanticscholar   +1 more source

Polycythemia vera and idiopathic erythrocytosis: comparison of clinical and laboratory parameters [PDF]

, 2004
Objective: To evaluate the various clinical and laboratory parameters of Polycythemia vera and idiopathic erythrocytosis in order to differentiate between two entities at the Aga Khan University Hospital. Methods: Twenty six patients of polycythemia vera
Usman, M., Bilwani, F., Kakepoto, G. N., Adil, Salman, Sajid, R., Khurshid, Mohammad   +5 more
core   +1 more source